UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) ~~of the Securities Exchange Act of 1934~~

~~Date~~ of ~~Report~~the ~~(Date~~Securities ofExchange ~~earliest~~Act ~~event~~of ~~reported):~~1934 ~~June 22, 2017~~

Date of Report (Date of earliest event reported): July 24, 2017

UNILIFE CORPORATION

(Exact name of Registrant as Specified in Charter)

Delaware

001-34540

27-1049354

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)


250 Cross Farm Lane, York, Pennsylvania		17406
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (717) 384-3400

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 81.01. ~~Other~~ ~~Events~~Entry into a Material Definitive Agreement.

As previously reported in the ~~Company’s~~ Current Report on Form 8-K that Unilife Corporation (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) on April 12, 2017, ~~Unilife Corporation (~~the “Company”) and its U.S. subsidiaries, Unilife Medical Solutions, Inc. (“UMSI”) and Unilife Cross Farm, LLC (together with UMSI and the Company, the “Debtors”) filed voluntary petitions in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) for relief under Chapter 11 of the United States Bankruptcy Code, as amended. On May 10, 2017, the Company announced that as a result of the bankruptcy, the Company intends to adopt a modified reporting program with respect to its reporting obligations under the federal securities laws. In lieu of filing annual reports on Form 10-K and quarterly reports on Form 10-Q, the Company will file with the SEC a current report on Form 8-K that will have attached to it the monthly financial reports required by the Bankruptcy Court.

On ~~June~~July 14, 222017, the Debtors received bids for their assets from various parties and on July 17, 2017, the ~~Company~~Debtors ~~submitted~~held toan auction with such bidders. On July 19, 2017, the Bankruptcy Court ~~its~~held ~~monthly~~a ~~financial~~hearing ~~reports~~to ~~for~~consider ~~itself~~approval of asset purchase agreements (each, “Asset Purchase Agreement”) between the applicable Debtors and ~~its~~certain Uof the successful bidders, Hikma Pharmaceuticals LLC (“Hikma”), Amgen Inc.S. ~~subsidiaries~~(“Amgen”) and UNL Holdings LLC (“UNL”), for the ~~month~~sale ~~ended~~of ~~May 31,~~substantially ~~2017~~all (assets of the Debtors (“~~Monthly~~Asset ~~Reports~~Sales”) with the Bankruptcy Court. UNL submitted its bid as a designee of ROS Acquisition Offshore LP (“ROS”). By order dated July 21, 2017, the Bankruptcy Court approved the Asset Sales pursuant to the Asset Purchase Agreements. The ~~Monthly~~execution ~~Reports~~of ~~are~~the ~~filed~~Asset Purchase Agreements and closing of the Asset Sales contemplated under each Asset Purchase Agreement occurred as ~~Exhibit~~of 99July 24, 2017.1 toThe ~~this~~Debtors ~~Form~~received ~~8-K~~no cash consideration as a result of the Asset Sales because each of the purchasers of the assets was, or was acting on behalf of, a secured creditor of one or more of the Debtors and no such purchaser bid an amount in excess of the amount of its secured debt. The Asset Purchase Agreements are ~~incorporated~~described ~~herein~~in bygreater ~~this~~detail ~~reference~~below.

~~Cautionary~~Pursuant ~~Statement~~to ~~Regarding~~the Asset Purchase Agreement effective as of July 20, 2017, between UMSI, Unitract Syringe Pty Ltd. (“Unitract”) and Hikma, Hikma (i) licensed certain intellectual property of the ~~Monthly~~Debtors ~~Reports~~and Unitract and (ii) purchased certain physical assets and intellectual property of the Debtors and Unitract related to Unifill Nexus™ luer connection syringe and the components thereof and the Unifill Nexus SelectTM syringe and the components thereof in consideration of a credit bid and release of Hikma’s secured claim against such assets in the amount of $7.5 million and agreeing to certain releases in connection with certain existing agreement between the parties.

~~The~~Pursuant ~~Monthly~~to ~~Reports~~the ~~contain~~Asset ~~financial~~Purchase ~~statements~~Agreement ~~and~~entered ~~other~~into ~~financial~~as ~~information~~of ~~that~~July 17, ~~have~~2017, ~~not~~by ~~been~~and among ~~audited~~the orCompany, ~~reviewed~~UMSI, bythe ~~any~~Company’s ~~independent~~non-debtor ~~public~~Australian ~~accounting~~subsidiaries, ~~firm~~Unitract and ~~may~~Unilife beMedical ~~subject~~Solutions toPty ~~future~~Limited ~~reconciliation~~(the or“Non-Debtor Subsidiaries”), ~~adjustments.~~and ~~The~~Amgen ~~Monthly~~Inc. ~~Reports~~(“Amgen”), ~~are~~Amgen inpurchased acertain ~~format~~physical ~~prescribed~~assets byand ~~applicable~~intellectual ~~bankruptcy~~property ~~laws~~of ~~and~~the ~~should~~Debtors ~~not~~related beto ~~used~~the ~~for~~Company’s ~~investment~~1mL ~~purposes.~~wearable ~~The~~injector ~~Monthly~~patents ~~Reports~~in ~~may~~consideration ~~not~~of bethe ~~indicative~~credit bid of the ~~Company’s~~Note Obligations ~~financial~~(as ~~condition~~defined orin ~~operating~~the ~~results.~~Amgen ~~Results~~Asset ~~set~~Purchase ~~forth~~Agreement) inand release of the ~~Monthly~~sellers ~~Reports~~from ~~should~~the ~~not~~Note beObligations ~~viewed~~in asthe ~~indicative~~aggregate amount of ~~future results~~$10,000,000.

~~Forward~~Pursuant to the Asset Purchase Agreement entered into as of July 17, 2017, by and among the Debtors, the Non-~~Looking~~Debtor ~~Statements~~Subsidiaries and UNL Holdings LLC (“UNL”), UNL purchased the remaining physical assets and intellectual property of the Debtors and the Non-Debtor Subsidiaries in consideration of the credit bid by ROS of the Obligations (as defined in the UNL Asset Purchase Agreement) and the indebtedness from the debtor-in-possession term credit facility and release of the Debtors from the Obligations in the aggregate amount of $25,000,000.

~~This~~The ~~report~~foregoing ~~contains~~descriptions ~~forward-looking~~of ~~statements. All statements that address operating performance, events or developments that~~ the ~~Company~~Asset ~~expects~~Purchase orAgreements ~~anticipates~~do ~~may~~not orpurport ~~will~~to ~~occur~~be incomplete ~~the~~and ~~future~~ are ~~forward-looking~~qualified ~~statements.~~in their ~~These~~entirety ~~forward-looking~~by ~~statements~~reference ~~are based on management’s beliefs and assumptions and on information currently available~~ to the Company’s management. The Company’s management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as full text of the ~~date~~Asset ~~when~~Purchase ~~made~~Agreements. ~~The~~Copies ~~Company does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result~~ of ~~new~~the ~~information,~~Asset ~~future~~Purchase ~~events~~Agreements ~~or otherwise, except~~ as ~~required~~approved by ~~law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from~~ the ~~Company’s~~Bankruptcy ~~historical~~Court ~~experience~~can ~~and~~be ~~the~~found ~~Company’s~~at ~~present expectations or projections~~http://www. ~~These risks and uncertainties include, but are not limited to, those described in “Item 1A~~omnimgt. ~~Risk Factors” and elsewhere in the Company’s Annual Report on Form 10-K, those described from time to time in other reports which the Company files with the SEC, and other risks and uncertainties~~com/cmsvol2/pub_47177/635415_286.pdf.

Item 9 2.01. ~~Financial~~Completion ~~Statements~~of ~~and~~Acquisition ~~Exhibits.~~or Disposition of Assets.

~~(d) Exhibits~~The information set forth above under Item 1.01 is hereby incorporated by reference into this Item 2.01.

Exhibit Number		Description
Exhibit 99.1		Monthly Financial Report of Unilife Corporation, et al. for Month Ending May 31, 2017

Item 8.01. Other Events.

~~SIGNATURES~~The Company expects to wind down and dissolve the Debtors and Non-Debtor Subsidiaries in accordance with applicable law. In light of the consideration received, the Company expects that there will be no recovery by the Company’s stockholders after a pro rata payment to the Company’s unsecured creditors.

~~Pursuant~~On toMay 10, 2017, the ~~requirements~~Company announced that, as a result of the ~~Securities~~bankruptcy, ~~Exchange~~the ~~Act~~Company intends to adopt a modified reporting program with respect to its reporting obligations under the federal securities laws. In lieu of ~~1934~~filing annual reports on Form 10-K and quarterly reports on Form 10-Q, the Company has ~~duly~~filed ~~caused~~and ~~this~~intends ~~Report~~to continue to befile ~~signed~~with the SEC a current report on ~~its~~Form ~~behalf~~8-K that attaches the monthly financial reports required by the ~~undersigned~~Bankruptcy ~~hereunto~~Court. ~~duly~~On ~~authorized~~July 27, 2017, the Company submitted to the Bankruptcy Court its monthly financial reports for itself and its U.S. subsidiaries for the month ended June 30, 2017 (the “Monthly Reports”). The Monthly Reports are filed as Exhibit 99.1 to this Form 8-K and are incorporated herein by this reference.

Cautionary Statement Regarding the Monthly Reports

~~EXHIBIT~~The Monthly ~~INDEX~~Reports contain financial statements and other financial information that have not been audited or reviewed by any independent public accounting firm and may be subject to future reconciliation or adjustments. The Monthly Reports are in a format prescribed by applicable bankruptcy laws and should not be used for investment purposes. The Monthly Reports may not be indicative of the Company’s financial condition or operating results. Results set forth in the Monthly Reports should not be viewed as indicative of future results.

EXHIBIT NUMBER		DESCRIPTION
99.1		Monthly Financial Report of Unilife Corporation, et al. for Month Ending May 31, 2017.

Forward-Looking Statements

This report contains forward-looking statements. All statements that address operating performance, events or developments that the Company expects or anticipates may or will occur in the future are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to the Company’s management. The Company’s management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. The Company does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from the Company’s historical experience and the Company’s present expectations or projections. These risks and

uncertainties include, but are not limited to, those described in “Item 1A. Risk Factors” and elsewhere in the Company’s Annual Report on Form 10-K, those described from time to time in other reports which the Company files with the SEC, and other risks and uncertainties.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.


Exhibit Number		Description

Exhibit 99.1		Monthly Financial Report of Unilife Corporation, et al. for Month Ending June 30, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX


EXHIBIT NUMBER		DESCRIPTION

99.1		Monthly Financial Report of Unilife Corporation, et al. for Month Ending June 30, 2017.

Unilife Corporation

Date: June 26, 2017

/s/ John Ryan

Name: John Ryan

Title: President and Chief Executive Officer

Filing Compare · Unilife Corp